Last reviewed · How we verify
NCT03958721
Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
Phase 1 trial testing Capecitabine in Resistant Breast Cancer in 20 participants. Completed in 26 October 2023.
26 October 2023
Quick facts
| Lead sponsor | A Bapsi Chakravarthy, MD |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 18 July 2019 |
| Primary completion | 26 October 2023 |
| Estimated completion | 26 October 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Capecitabine (capecitabine) — full drug profile →
- Radiotherapy — full drug profile →
Conditions studied
- Resistant Breast Cancer — all drugs for Resistant Breast Cancer →
- Non-metastatic Invasive Breast Cancer — all drugs for Non-metastatic Invasive Breast Cancer →
Sponsor
A Bapsi Chakravarthy, MD
Who can join
18 and older, female only, with Resistant Breast Cancer or Non-metastatic Invasive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, prospective, non-randomized, feasibility study evaluating concurrent capecitabine-radiotherapy in participants with Resistant Breast Cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Modulating the Radiation Response for Improved Outcomes in Breast Cancer.
Pesch AM, Pierce LJ, Speers CW. · · 2021 · cited 11× · PMID 34250414 · DOI 10.1200/po.20.00297
Verify or expand the search:
- PubMed search for NCT03958721
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Capecitabine
Trials testing the same drug.
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT06622057 — D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer · Phase 3 · not yet recruiting
- NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03958721 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by A Bapsi Chakravarthy, MD
- Last refreshed: 27 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03958721.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing